News
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
3d
GlobalData on MSNMounjaro and Zepbound fuel strong Q2 growth for Eli LillyEli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...
Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...
3don MSN
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...
Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand Eli Lilly raised its outlook for the year after revenue surged in its latest quarter on continued demand for its ...
A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...
Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results